TAIYO HOLDINGS CO.,LTD. FY2027 Q1 Earnings Report

Quick View

Executive Summary

The first quarter of the fiscal year ending March 2026 delivered higher revenue and profits, with a significant increase in the growth rate of earnings, driven by improved profitability in the Electronics Business. Revenue was ¥390.2B (+17.6% YoY), Operating Income was ¥105.0B (+48.9%), Ordinary Income was ¥112.2B (+68.5%), and Net Income attributable to owners of the parent was ¥75.0B (+61.8%), with all items recording double-digit growth. The Operating Income margin improved to 26.9% from 21.3% in the previous year, a +5.6pt improvement, while the gross profit margin also expanded to 51.5% from 47.3%. The primary factors behind the earnings growth were the expansion of revenue and improved profitability in the Electronics Business, while the Medical and Pharmaceutical Business showed contrasting declines in both revenue and earnings.

Factors Affecting Performance

【Revenue】Revenue was ¥390.2B, representing a +17.6% YoY increase. By segment, the Electronics Business led company-wide growth with revenue of ¥280.5B (+26.2%), reaching a 71.9% share of total revenue. Meanwhile, the Medical and Pharmaceutical Business reported revenue of ¥92.0B (-2.3%), while Other Businesses (including ICT&S) increased revenue to ¥19.0B (+17.7%). Nearly all of the company-wide revenue growth was attributable to the expansion of the Electronics Business.

【Profit and Loss】Operating Income was ¥105.0B (+48.9%), and the Operating Income margin was 26.9%, improving by +5.6pt from 21.3% in the previous year. The primary driver of profit improvement was also the Electronics Business, which generated Operating Income of ¥97.6B (+57.4%) and maintained high profitability with a 34.8% margin. In contrast, the Medical and Pharmaceutical Business deteriorated, with Operating Income of ¥7.7B (-44.0%) and a margin of 8.4%, down -6.2pt from 14.6% in the previous year, widening the profitability gap between segments. Ordinary Income was ¥112.2B (+68.5%), reflecting non-operating income of ¥12.6B and non-operating expenses of ¥5.5B. After recording an extraordinary loss of ¥9.0B, Net Income attributable to owners of the parent was ¥75.0B (+61.8%). The key characteristics were growth in both revenue and earnings, together with an acceleration in earnings growth driven by strong operating leverage.

Segment Analysis

The Electronics Business is the core business, accounting for 71.9% of total company revenue and approximately 91.5% of total reported segment profit, with revenue of ¥280.5B (+26.2%), Operating Income of ¥97.6B (+57.4%), and a margin of 34.8%. The Medical and Pharmaceutical Business shifted to declines in both revenue and earnings, with revenue of ¥92.0B (-2.3%), Operating Income of ¥7.7B (-44.0%), and a margin of 8.4%, down from 14.6% in the previous year, representing a significant deterioration in profitability. Other Businesses (including ICT&S) showed a rapid recovery despite their small scale, with revenue of ¥19.0B (+17.7%) and Operating Income of ¥1.4B (+521.9%). Company-wide Operating Income growth is structurally almost entirely dependent on improved operating rates and product mix in the Electronics Business, while the decline in profitability of the Medical and Pharmaceutical Business highlights the increasing polarization within the portfolio.

Key Financial Metrics

【Profitability】Both the Operating Income margin of 26.9% (+5.6pt from 21.3% in the previous year) and the Net Income margin of 19.2% (+5.2pt YoY approximately) improved, while the gross profit margin also expanded to 51.5% from 47.3% in the previous year. 【Cash Flow Quality】Cash and deposits increased to ¥457.0B from ¥432.0B in the previous year, while accounts receivable increased to ¥375.1B (¥343.2B in the previous year, +9.4%) and inventories to ¥107.2B (¥103.3B in the previous year, +3.8%), indicating an expansion in working capital. The accumulation of inventories and receivables accompanying revenue growth may be affecting the speed of cash conversion. 【Investment Efficiency】ROE was 5.9%, and BPS was ¥1,135.13 (¥1,040.16 in the previous year, +9.1%). Growth in total assets (¥2,118.4B) was relatively moderate compared with profit growth. 【Financial Soundness】The Equity Ratio improved to 59.6%, up +2.3pt from 57.3% in the previous year. Current assets were ¥1,090.6B against current liabilities of ¥446.0B, resulting in a high current ratio of 244.5%. Against interest-bearing debt totaling ¥536.6B—comprising short-term borrowings of ¥17.5B, long-term borrowings due within one year of ¥163.4B, and long-term borrowings of ¥355.8B—the company held cash of ¥457.0B. Operating Income coverage of interest expense of ¥1.8B was approximately 58 times, indicating high resilience to interest burdens.

Cash Flow Analysis

Although the disclosed items in the statement of cash flows are limited, changes in the balance sheet provide insight into cash movements. Cash and deposits increased to ¥457.0B from ¥432.0B in the same period of the previous year, suggesting that profit generation from operating activities is supporting the cash base. Meanwhile, accounts receivable increased to ¥375.1B (¥343.2B in the previous year), and inventories increased to ¥107.2B (¥103.3B in the previous year), indicating that the expansion of working capital accompanying revenue growth is affecting cash efficiency. Accounts payable increased to ¥115.5B (¥95.0B in the previous year, +21.6%), partially offsetting the increase in working capital through the use of trade payables. Short-term borrowings increased to ¥17.5B (¥12.7B in the previous year, +37.2%), suggesting that financing was undertaken in response to increased working capital requirements. Overall, while growth in operating-level earnings is supporting the cash base, increases in accounts receivable and inventories are partially slowing the pace of cash generation.

Quality of Earnings

Operating Income of ¥105.0B is the core of recurring earning power. Non-operating income of ¥12.6B, equivalent to 3.2% of revenue, consisted primarily of items such as subsidy income and interest income and remained limited in scale. Non-operating expenses were ¥5.5B, primarily comprising interest expense of ¥1.8B and foreign exchange losses of ¥1.4B, with fluctuations in interest rates and foreign exchange acting as sources of volatility in Ordinary Income. Against Ordinary Income of ¥112.2B, profit before tax after deducting the extraordinary loss of ¥9.0B was ¥103.2B. After corporate income taxes and other taxes of ¥28.1B, representing an effective tax rate of 27.3%, Net Income attributable to owners of the parent was ¥75.0B. The gap between Ordinary Income and Net Income was primarily attributable to the extraordinary loss and tax burden, while profitability at the operating and ordinary income levels remained solid. Comprehensive Income was ¥100.3B, exceeding Net Income of ¥75.1B, supported by an increase in foreign currency translation adjustments of ¥7.4B and valuation difference on available-for-sale securities of ¥17.9B. The gap between Comprehensive Income and Net Income expanded compared with the approximately ¥7.6B gap in the same period of the previous year, warranting attention because temporary valuation factors were strongly reflected in Comprehensive Income.

Earnings Forecast and Guidance

The full-year plan calls for revenue of ¥1,491.0B (+8.2%), Operating Income of ¥364.0B (+11.9%), Ordinary Income of ¥363.0B (+12.6%), and forecast EPS of ¥228.26. Q1 progress rates were 26.2% for revenue, 28.9% for Operating Income, 30.9% for Ordinary Income, and 29.5% for Net Income (Net Income attributable to owners of the parent of ¥75.0B ÷ full-year forecast of ¥254.0B). These figures exceeded the quarterly evenly distributed progress rate of 25%, with profit items, in particular, progressing ahead of schedule. The high profitability of the Electronics Business generated profit contributions at a quarterly pace exceeding the full-year plan, and the sustainability of full-year progress will depend on whether this profitability can be maintained throughout the year.

Shareholder Returns

For the current fiscal year (fiscal year ending March 2027), the company has indicated a policy of making neither an interim dividend nor a year-end dividend, resulting in a Payout Ratio of 0%. Although dividends were paid in the previous fiscal year on a pre-stock-split basis, the company has shifted to a no-dividend policy for the current fiscal year. Given its financial base of cash and deposits of ¥457.0B and an Equity Ratio of 59.6%, the company is not constrained by its ability to pay dividends; rather, capital allocation priorities may have been placed on investments and other uses.

Risk Factors

1. Segment concentration risk: The Electronics Business accounts for 71.9% of revenue and more than 90% of total reported segment profit, creating a structure in which fluctuations in demand or a decline in operating rates in this business could have a significant impact on company-wide performance.

2. Changes in working capital efficiency: Accounts receivable increased to ¥375.1B (¥343.2B in the previous year, +9.4%), and inventories increased to ¥107.2B (¥103.3B in the previous year, +3.8%). Working capital has grown significantly relative to the pace of revenue growth, requiring monitoring of cash conversion speed.

3. Decline in profitability of the Medical and Pharmaceutical Business: Revenue was ¥92.0B (-2.3%), Operating Income was ¥7.7B (-44.0%), and the margin was 8.4%, down -6.2pt from 14.6% in the previous year, indicating a shift in the earnings structure within the portfolio.

Industry Benchmark (For Reference; Compiled by the Company)

Profitability and Returns

Profitability metrics are significantly above the manufacturing industry median and rank among the higher levels within the industry.

Growth and Capital Efficiency

The revenue growth rate also exceeded the industry median, with growth surpassing the IQR upper limit of 14.7%.

※Source: Compiled by the Company

Key Earnings Highlights

1. Q1 progress rates against the full-year plan were 28.9% for Operating Income, 30.9% for Ordinary Income, and 29.5% for Net Income, exceeding the evenly distributed progress rate of 25%. The primary factor was the high profitability of the Electronics Business.

2. While dependence on the Electronics Business for profit has increased, the margin of the Medical and Pharmaceutical Business declined from 14.6% in the previous year to 8.4%, indicating an ongoing change in the earnings structure within the business portfolio.

3. For the fiscal year ending March 2027, a no-dividend policy has been indicated for both the interim and year-end dividends. This should be observed as a turning point in capital allocation policy, given the high levels of cash and deposits and the strong Equity Ratio.

Theoretical Share Price (Reference Value)

This is a reference range mechanically calculated solely from publicly available data using a residual income model (Ohlson-type model with an explicit 5-year fade). It is not a forecast of the market share price or a recommendation to take any specific investment action.

Sensitivity: ¥1,539–¥1,633 at ±1% for the cost of equity, and ¥1,573–¥1,603 at ±0.1 for ω.

Notes:

• Net assets as of the end of the quarter are used (there is a timing difference from the full-year forecast).

(Calculation model: Residual income model / Interest rate reference month: 2026-06 / This value does not forecast or guarantee the future share price)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting a professional as necessary.

---End of Report---